Novartis trial shows no benefits from Pear's schizophrenia app as CEO cites trial irregularities

Jan 14, 2021 jonah.comstock@mobihealthnews.com (Jonah Comstock), Mobile Health News

The results will not impact the current rollout of a new version of the app, under special FDA guidelines.